Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "kexin"

Sichuan Kexin Mechanical and Electrical Equipment actual contr...

Thomson Reuters is the world's largest international multimedia news agency, providing investing news , world news , business news , technology news , headline news, small business news, news alerts, personal finance , stock market , and mutual ... Reuters UK, 1 week ago
Sichuan Kexin, Nigeria OBAX Plan to Set up JV Individual.com, 2 weeks ago

8 images for kexin

BBC, 1 week ago
Sporting Life, 2 weeks ago
Aiken Today, 3 weeks ago
Miami Herald, 1 month ago
Sporting Life, 1 month ago
Sportsnet.ca, 1 month ago
Pharmaceutical Business Review, 2 months ago
Channel NewsAsia, 2 months ago

Amgen Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha (evolocumab) In Japan

Repatha is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" ...
 Morningstar.com1 week ago ACC: PCSK9 Inhibitors Reduce LDL Cholesterol in Long Term  Physician's Briefing1 week ago Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data  Bio-Medicine3 weeks ago Move over Sovaldi: Could PCSK9 inhibitors be a bigger cost challenge?  Formulary Journal1 month ago
[x]  
Miami Herald

Fontana, Migunov win at short track speedskating World Cup

Fontana led from start to finish to beat European champion Elise Christie of Britain and Fan Kexin of China. Canada won the women's 3,000 relay final for its first relay victory of the season, while the Netherlands won the
 MySanAntonio1 month ago Koreans dominate short track speedskating World Cup  Yahoo! Singapore1 month ago China finish short track speedskating World Cup without gold  Ecns.cn1 month ago
[x]  

LIPOPROTEIN(A) IN FAMILIAL HYPERCHOLESTEROLEMIA WITH PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 GAIN-OF-FUNCTION MUTATIONS: IMPLICATION OF RESIDUAL RISK IN STATIN-ERA

Note: Since your browser does not support Javascript, you must press the Continue button once
 Journal of the American College of Cardiology1 week ago SAFETY AND EFFICACY OF LY3015014, A NEW MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) WITH AN INHERENTLY LONGER DURATION OF ACTION, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGIN  Journal of the American College of Cardiology1 week ago NOVEL MECHANISM FOR THE SUSTAINED DURABILITY OF PROPROTEIN CONVERTASE SUBTILISIN-KEXIN TYPE 9 MONOCLONAL ANTIBODY LY3015014  Journal of the American College of Cardiology1 week ago
Medical News Today

High intensity statin therapy does not affect LDL cholesterol lowering with the PCSK9 inhibitor alirocumab

LDL cholesterol is the proven lipid target for preventing heart disease and stroke (cardiovascular disease). Inhibitors of PCSK9 (proprotein convertase subtilisin/kexin type 9), a protein which plays a key role in regulating plasma levels of LDL ...
 Medical News Today2 days ago New cholesterol-lowering drug 'could halve risk of heart attack, stroke'  Medical News Today1 week ago After 1 year, patients on new drug fare better than standard therapy  EurekAlert!1 week ago Evolocumab for cholesterol: After one year, patients on new drug fare better than standard therapy  Science Daily1 week ago
[x]  

+ Prof. Sumio Iijima Speaks in Qizhen Global Vision Lecture Series [03-24-2015]

"It's far from a rational idea that reers focus exclusively on ultimate goals; rather, they shouldn't neglect every minor finding while doing re," said Prof. Sumio Iijima in his speech in Qizhen Global Vision Lecture Series. On the afternoon of ...
 Noodls4 days ago

Alirocumab Effective on Against LDL-C Top of Max-Dose Statin

GLASGOW, SCOTLAND — Background statin therapy, even the use of high-dose statin therapy, did not affect the ability of alirocumab (Sanofi/Regeneron) to reduce LDL-cholesterol levels in patients at high cardiovascular risk, according to a new ...
 General Medicine eJournal4 days ago Statin-associated muscle symptoms: impact on statin therapy--European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management  European Heart Journal1 month ago

2 Minute Medicine Rewind March 16 March 22, 2015

In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events Proportein convertase subtilisin-kexin ...
 2 Minute Medicine4 days ago

Astellas Pharma : - ANNOUNCEMENT OF MARKETING APPROVAL SUBMISSION TO MHLW (JAPAN) FOR LDL CHOLESTEROL-LOWERING MEDICATION EVOLOCUMAB

Release date- 20032015 - TOKYO - Astellas Pharma Inc. (Headquarters, Tokyo ; President and CEO, Yoshihiko Hatanaka ; hereafter referred to as Astellas Pharma ) and Amgen Astellas BioPharma K.K. (Headquarters, Tokyo ; General Manager and ...
 4 Traders6 days ago ASTELLAS - ANNOUNCEMENT OF MARKETING APPROVAL SUBMISSION TO MHLW (JAPAN) FOR LDL CHOLESTEROL-LOWERING MEDICATION EVOLOCUMAB  Pharmacy Choice5 days ago Astellas Pharma : ANNOUNCEMENT OF MARKETING APPROVAL SUBMISSION TO MHLW (JAPAN) FOR LDL CHOLESTEROL-LOWERING MEDICATION EVOLOCUMAB  4 Traders1 week ago ANNOUNCEMENT OF MARKETING APPROVAL SUBMISSION TO MHLW (JAPAN) FOR LDL CHOLESTEROL-LOWERING MEDICATION EVOLOCUMAB  Noodls1 week ago
EuroInvestor

Sanofi and Regeneron Release 18-Month Results of Odyssey Long Term Trial with Praluent (alirocumab) Published in The New England Journal of Medicine [Professional Services Close - Up]

Sanofi and Regeneron Pharmaceuticals reported that 18-month (78- week) results of a Phase 3 trial of Praluent (alirocumab), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New ...
 Pharmacy Choice6 days ago Sanofi et Regeneron annoncent la publication dans The New England..  ADVFN Australia1 week ago Sanofi, Regeneron: 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine  EuroInvestor1 week ago SANOFI : and Regeneron Release 18-Month Results of Odyssey Long Term Trial with Praluent (alirocumab) Published in The New England Journal of Medicine  4 Traders1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less